Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Aug. 31, 2018
Aug. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (12,223) $ (12,557)
Adjustments required to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 2,984 2,817
Share in losses of associated company 732 348
Depreciation and amortization expenses 1,833 1,874
Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date fair value (4,509) 0
Change in fair value of warrants and embedded derivatives 11 (230)
Change in fair value of convertible bonds 0 (157)
Interest expenses accrued on loans and convertible loans (including amortization of beneficial conversion feature) 2,856 818
Changes in operating assets and liabilities, net of business combination:    
Increase in accounts receivable (2,818) (682)
Decrease in related parties, net (379) 0
Increase in inventory (848) (484)
Increase (decrease) in other assets 65 (1)
Increase in prepaid expenses and other accounts receivable (148) (818)
Decrease in accounts payable (1,723) (1,230)
Increase (decrease) in accrued expenses and other payables (686) 192
Increase (decrease) in employee and related payables (820) 554
Increase in deferred income 705 3,268
Increase in advance payments and receivables on account of grant, net 815 2,358
Increase in deferred taxes 1,680 494
Net cash used in operating activities (12,473) (3,436)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (4,430) (639)
Disposals of property and equipment 0 31
Acquisition of CureCell , net of cash acquired (See ) 58 0
Acquisition of Atvio , net of cash acquired (See ) 245 0
Investments in long term deposit (92) 0
Investments in associate 0 (835)
Net cash used in investing activities (4,219) (1,443)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Short-term line of credit 0 (21)
Proceeds from issuance of shares and warrants (net of transaction costs) 12,666 4,307
Proceeds from issuance of convertible loans (net of transaction costs) 720 4,932
Repayment of convertible loans and convertible bonds (177) (3,766)
Proceeds from receipts on account of shares to be allotted 3,626 0
Increase in redeemable non-controlling interests 14,007 0
Repayment of short and long-term debt (331) (1,102)
Net cash provided by financing activities 30,511 4,350
NET CHANGE IN CASH AND CASH EQUIVALENTS 13,819 (529)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (201) 400
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 3,519 891
CASH AND CASH EQUIVALENTS AT END OF PERIOD 17,137 762
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES    
Conversion of loans and bonds (including accrued interest) to common stock and warrants 7,511 106
Classification of loan receivable into services to be received from CureCell $ 813 $ 0